Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier

Sumio Ohtsuki, Satoko Hori, Tetsuya Terasaki

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The blood-brain barrier (BBB) segregates the circulating blood from interstitial fluid in the brain and restricts drug permeability into the brain. Recent studies have revealed that the BBB exhibits not only blood-to-brain influx transport for the supply of nutrients, but also brain-to-blood efflux transport to excrete drugs and endogenous compounds. The influx transport system allows drugs to enter the brain. L-DOPA is transported into the brain by the large neutral amino acid transport system, system L. A cationic μ-opioid peptide analogue enters the brain by adsorptive-mediated endocytosis. In contrast, efflux transport limits the distribution of drugs in the brain. The ATP binding cassette transporter B1 (ABCB1) mediates the efflux transport of lipophilic drugs at the BBB by using ATP energy. Furthermore, organic anion transporter 3 (OAT3) is expressed at the BBB and mediates the efflux transport of homovanillic acid, a dopamine metabolite. This efflux transport is also likely to be involved in the transport of anionic drugs such as 6-mercaptopurine and acyclovir. Clarifying the BBB transport could give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS diseases and BBB functions.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalFolia Pharmacologica Japonica
Volume122
Issue number1
DOIs
Publication statusPublished - 2003 Jul 22
Externally publishedYes

Fingerprint

Blood-Brain Barrier
Brain
Pharmaceutical Preparations
Neutral Amino Acid Transport Systems
Organic Anion Transporters
6-Mercaptopurine
Homovanillic Acid
ATP-Binding Cassette Transporters
Opioid Peptides
Acyclovir
Central Nervous System Diseases
Extracellular Fluid
Endocytosis
Permeability
Dopamine
Adenosine Triphosphate
Food

Keywords

  • Blood-brain barrier
  • Brain capillary endothelial cells
  • Efflux transport
  • Influx transport
  • Transporter

ASJC Scopus subject areas

  • Pharmacology

Cite this

Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier. / Ohtsuki, Sumio; Hori, Satoko; Terasaki, Tetsuya.

In: Folia Pharmacologica Japonica, Vol. 122, No. 1, 22.07.2003, p. 55-64.

Research output: Contribution to journalReview article

Ohtsuki, Sumio ; Hori, Satoko ; Terasaki, Tetsuya. / Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier. In: Folia Pharmacologica Japonica. 2003 ; Vol. 122, No. 1. pp. 55-64.
@article{ce208906574244acbbec6d2c1d3c805a,
title = "Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier",
abstract = "The blood-brain barrier (BBB) segregates the circulating blood from interstitial fluid in the brain and restricts drug permeability into the brain. Recent studies have revealed that the BBB exhibits not only blood-to-brain influx transport for the supply of nutrients, but also brain-to-blood efflux transport to excrete drugs and endogenous compounds. The influx transport system allows drugs to enter the brain. L-DOPA is transported into the brain by the large neutral amino acid transport system, system L. A cationic μ-opioid peptide analogue enters the brain by adsorptive-mediated endocytosis. In contrast, efflux transport limits the distribution of drugs in the brain. The ATP binding cassette transporter B1 (ABCB1) mediates the efflux transport of lipophilic drugs at the BBB by using ATP energy. Furthermore, organic anion transporter 3 (OAT3) is expressed at the BBB and mediates the efflux transport of homovanillic acid, a dopamine metabolite. This efflux transport is also likely to be involved in the transport of anionic drugs such as 6-mercaptopurine and acyclovir. Clarifying the BBB transport could give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS diseases and BBB functions.",
keywords = "Blood-brain barrier, Brain capillary endothelial cells, Efflux transport, Influx transport, Transporter",
author = "Sumio Ohtsuki and Satoko Hori and Tetsuya Terasaki",
year = "2003",
month = "7",
day = "22",
doi = "10.1254/fpj.122.55",
language = "English",
volume = "122",
pages = "55--64",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "1",

}

TY - JOUR

T1 - Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier

AU - Ohtsuki, Sumio

AU - Hori, Satoko

AU - Terasaki, Tetsuya

PY - 2003/7/22

Y1 - 2003/7/22

N2 - The blood-brain barrier (BBB) segregates the circulating blood from interstitial fluid in the brain and restricts drug permeability into the brain. Recent studies have revealed that the BBB exhibits not only blood-to-brain influx transport for the supply of nutrients, but also brain-to-blood efflux transport to excrete drugs and endogenous compounds. The influx transport system allows drugs to enter the brain. L-DOPA is transported into the brain by the large neutral amino acid transport system, system L. A cationic μ-opioid peptide analogue enters the brain by adsorptive-mediated endocytosis. In contrast, efflux transport limits the distribution of drugs in the brain. The ATP binding cassette transporter B1 (ABCB1) mediates the efflux transport of lipophilic drugs at the BBB by using ATP energy. Furthermore, organic anion transporter 3 (OAT3) is expressed at the BBB and mediates the efflux transport of homovanillic acid, a dopamine metabolite. This efflux transport is also likely to be involved in the transport of anionic drugs such as 6-mercaptopurine and acyclovir. Clarifying the BBB transport could give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS diseases and BBB functions.

AB - The blood-brain barrier (BBB) segregates the circulating blood from interstitial fluid in the brain and restricts drug permeability into the brain. Recent studies have revealed that the BBB exhibits not only blood-to-brain influx transport for the supply of nutrients, but also brain-to-blood efflux transport to excrete drugs and endogenous compounds. The influx transport system allows drugs to enter the brain. L-DOPA is transported into the brain by the large neutral amino acid transport system, system L. A cationic μ-opioid peptide analogue enters the brain by adsorptive-mediated endocytosis. In contrast, efflux transport limits the distribution of drugs in the brain. The ATP binding cassette transporter B1 (ABCB1) mediates the efflux transport of lipophilic drugs at the BBB by using ATP energy. Furthermore, organic anion transporter 3 (OAT3) is expressed at the BBB and mediates the efflux transport of homovanillic acid, a dopamine metabolite. This efflux transport is also likely to be involved in the transport of anionic drugs such as 6-mercaptopurine and acyclovir. Clarifying the BBB transport could give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS diseases and BBB functions.

KW - Blood-brain barrier

KW - Brain capillary endothelial cells

KW - Efflux transport

KW - Influx transport

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=0038268754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038268754&partnerID=8YFLogxK

U2 - 10.1254/fpj.122.55

DO - 10.1254/fpj.122.55

M3 - Review article

C2 - 12843573

AN - SCOPUS:0038268754

VL - 122

SP - 55

EP - 64

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 1

ER -